Written & medically reviewed by Dr. Jignesh Gala, Vitreoretinal & Cataract Surgeon, Founder & Director — Crystal Clear Eye Clinic and Topax Eye Hospital, Mumbai. Last updated: 22 July 2026.

Retina Laser Treatment in Andheri West, Mumbai — PRP, Barrage, Focal & Micropulse Laser by Dr. Jignesh Gala (FRCS)

⚡ Quick answer: Retinal laser (photocoagulation) is a painless 10–20 minute OPD procedure that seals leaking vessels, shrinks abnormal new vessels, and barricades retinal tears before they detach. In Mumbai it costs ₹3,000–8,000 per sitting (PRP) or ₹8,000–25,000 per eye (barrage/focal) — full tables below. At Crystal Clear Eye Clinic, Andheri West, every laser is performed personally by retina surgeon Dr. Jignesh Gala (FRCS Glasgow, LVPEI-trained), with same-day emergency slots for retinal tears. Call 077188 85245.

First, a confusion worth clearing — because half of Mumbai Googles the wrong thing:

🔀 “Laser eye treatment” ≠ one thing. LASIK laser reshapes the front of the eye (cornea) to remove spectacles. Retina laser works at the back of the eye to stop bleeding, leakage and detachment — it does NOT remove your glasses. Different machines, different doctors, different diseases. This page is about retina laser, done by a vitreoretinal surgeon. (For spectacle removal, that’s our LASIK Hub at Topax — different team, same building trust.)

Dr. Jignesh Gala at The LASIK Hub Topax Eye Hospital — retina laser vs LASIK laser explained Mumbai

If your doctor has advised “retina laser” for diabetic retinopathy, a retinal tear, lattice degeneration, vein occlusion or CSR — this complete 2026 guide explains exactly what will happen, what it feels like, what it costs in Mumbai, how insurance pays, and what modern research (200+ verified references below) says about laser vs injections.

📋 In this guide:

What is retinal laser photocoagulation?
The 6 types of retinal laser — and which one you need
Conditions we treat with laser
Same-day emergency barrage laser for retinal tears
The procedure: 15 minutes, step by step — what you’ll feel
Laser vs injections — what the trials actually say
Costs in Mumbai & total-course math
Insurance & cashless for laser
Honest side-effects talk (and the no-scar micropulse option)
Why Dr. Jignesh Gala for your retina laser
Location, hours & suburbs
FAQs
Research library (180+ references)

1. What Is Retinal Laser Photocoagulation?

A retinal laser uses a focused beam of light (usually a 532 nm green laser) to create tiny, controlled burns on the retina. Depending on the pattern, those burns either seal leaking micro-aneurysms (focal laser), starve abnormal new vessels of oxygen demand so they shrink (PRP — panretinal photocoagulation), or weld the retina down around a tear so fluid can’t lift it off (barrage laser / laser retinopexy). It is the original sight-saving retina treatment — the landmark Diabetic Retinopathy Study proved it halved severe vision loss decades ago, and modern Cochrane reviews still confirm its role (Cochrane, 2014; NEJM, 2011).

Dr. Jignesh Gala performing retinal laser with indirect laser ophthalmoscope at Crystal Clear Eye Clinic Andheri West Mumbai

2. The 6 Types of Retinal Laser — and Which One You Need

Laser type	What it does	Used for	Sessions	Feels like
PRP (panretinal photocoagulation)	1,200–2,000 scatter burns reduce the retina’s oxygen demand → abnormal vessels shrink	Proliferative diabetic retinopathy, severe NPDR, ischemic CRVO (Prog Retin Eye Res, 2021)	2–3 sittings per eye	Pin-pricks, flickers of green light; mild ache
Barrage laser (laser retinopexy)	2–3 rows of burns weld retina around a tear/lattice → detachment blocked	Retinal tear, hole, lattice degeneration, high myopes (systematic review; 2024 outcomes)	Usually 1 sitting	Same pricks; 10–15 min
Focal / grid laser	Precise burns on leaking points near the macula	Non-center diabetic macular edema, BRVO macular edema (ETDRS; Cochrane BRVO)	1–2 sessions	Very mild; shorter sitting
Micropulse (subthreshold)	Invisible, scar-free stimulation of the retinal pump — no burn marks at all	Center-involved DME, chronic CSR — patients who fear scars (DIAMONDS RCT, 2022; J Clin Med review)	1–3 sessions	Nearly painless
Pattern-scanning (PASCAL-type)	Computer-delivered multi-spot patterns — faster, more comfortable PRP	PDR, large treatment areas (Cochrane techniques)	1–2 sittings	Shorter, better tolerated (pain comparison study)
YAG peripheral iridotomy (bonus)	A different laser — makes a microscopic drainage hole in the iris	Narrow-angle glaucoma prevention	1 sitting	A few clicks; 5 min

Note for searchers: “PRP” here means panretinal photocoagulation — not the platelet-rich-plasma skin treatment that floods Google results.

3. Conditions We Treat With Retina Laser in Andheri West

Proliferative diabetic retinopathy (PDR) — PRP laser remains a pillar of treatment, alone or combined with injections (our diabetic retinopathy care)
Retinal tear, hole or lattice degeneration — barrage laser before a tear becomes a detachment (also read every retinal detachment warning sign and sudden floaters guide)
Diabetic macular edema (selected cases) — focal/grid or scar-free micropulse, often sequenced with injections (DME treatment)
Retinal vein occlusion — grid laser for BRVO edema; PRP when ischemic CRVO grows abnormal vessels
Central serous chorioretinopathy (CSR) — micropulse laser for chronic fluid under the macula (Retina, 2015)
Retinopathy of prematurity (ROP) — urgent laser for premature babies’ retinas; Dr. Gala trained in ROP at LV Prasad Eye Institute (Lasers Med Sci; 2022 update)
Pre-LASIK / pre-cataract retina clearance — lasering weak spots before planned eye surgery in high myopes

4. 🚨 Same-Day Emergency Barrage Laser for Retinal Tears

Symptoms: sudden shower of floaters, flashes of light (especially at night), or a curtain/shadow at the edge of vision. A retinal tear can progress to full detachment within days — but caught today, a 15-minute barrage laser can weld it shut in the OPD, no surgery needed. Research confirms prophylactic laser of breaks dramatically reduces detachment risk (Clin Ophthalmol, 2025; Retina, 2020).

Call 077188 85245 and say “flashes and floaters” — we hold same-day emergency laser slots for exactly this. Evening hours till 9 pm mean you don’t have to wait till tomorrow.

5. The Procedure: 15 Minutes, Step by Step — What You’ll Actually Feel

Dilating drops (30–40 min wait — bring sunglasses)
Numbing drops — no injection needed for most lasers
Contact lens placed on the eye (or the indirect headset system for peripheral/PRP work) — you’ll feel gentle pressure
The laser: bright green flashes with a pin-prick or flicker sensation per shot. Pain studies rate retinal laser 2–4/10, and pattern/navigated systems score significantly lower than old single-spot machines (Clin Ophthalmol; Lasers Med Sci, 2020)
10–20 minutes later: done. Mild ache or gritty feeling for a few hours; vision stays dazzled/blurry from the bright light for 30–60 minutes
Aftercare: no drops needed in most cases; normal work next day; avoid heavy lifting for 2–3 days after barrage laser; review in 2–6 weeks to confirm the weld

Dr. Jignesh Gala examining retina patient before laser treatment at Andheri West eye clinic Mumbai

6. Laser vs Injections — What the Trials Actually Say (2026 View)

Patients often ask: “Doctor, laser or injection — which is better?” The honest, evidence-based answer:

For PDR, DRCR Protocol S showed ranibizumab injections were non-inferior to PRP at 2 years (JAMA, 2015) — but the 5-year follow-up found vision outcomes converged while injection patients needed ongoing treatment (JAMA Ophthalmol, 2018). CLARITY showed aflibercept also matches PRP at 1 year (Lancet, 2017).
2024–25 real-world and meta-analyses found anti-VEGF-first strategies reduce later vitrectomy, while laser-first costs far less over 5 years (JAMA Ophthalmol, 2024; Ophthalmol Retina, 2025; 5-year cost analysis).
Our protocol: injections first when the macula is swollen or bleeding is active; PRP laser for durable long-term control once stable — the combination approach supported by network meta-analysis (Acta Ophthalmol, 2021). Laser’s superpower: it’s often one-and-done for years, no monthly visits.
For retinal tears, there is no injection alternative — barrage laser is the only fix, and it works.

Full procedure details for injections here: intravitreal injection guide · anti-VEGF injection cost in Mumbai · eye injections explained simply · diabetic eye care in Mumbai · understanding diabetic eye disease.

7. Retina Laser Cost in Mumbai — Transparent 2026 Tables

Per-sitting pricing confuses everyone (a complete PRP needs 2–3 sittings), so here are both numbers:

Laser procedure	Per sitting (₹)	Total course per eye (₹)	Notes
PRP (diabetic retinopathy)	₹3,000 – ₹8,000	₹9,000 – ₹20,000 (2–3 sittings)	Pattern-scanning available for comfort
Barrage laser — retinal tear/hole	₹8,000 – ₹15,000	Usually single sitting	Same-day emergency slots
Barrage — extensive lattice / both eyes	—	₹15,000 – ₹35,000	Severity-graded after examination
Focal / grid laser (DME, BRVO)	₹10,000 – ₹25,000	1–2 sessions	OCT-guided targeting
Micropulse (subthreshold)	₹12,000 – ₹25,000	1–3 sessions	Scar-free option for macula
YAG peripheral iridotomy	₹5,000 – ₹10,000	Single sitting	Glaucoma prevention
ROP laser (premature babies)	₹15,000 – ₹25,000	Per session	Includes NICU coordination

Includes the procedure, consumables and scheduled review. Compare honestly: many Mumbai hospitals quote only per-sitting prices, or bundle lasers into “packages” without itemisation. Our written quote lists everything — consultation, OCT if needed, laser, and reviews.

8. Insurance & Cashless for Retina Laser

🏥 Direct cashless → Topax Eye Care (Topax Eye Hospital), Vile Parle East. Direct insurer tie-ups processed on the spot — walk in with your policy card, pre-authorisation while you wait.

🏥 Third-party cashless (TPA) → Crystal Clear Eye Clinic, Andheri West. TPA claims (25–30+ TPAs, GIPSA panels) processed with full documentation by our desk.

Laser-specific tip: OPD lasers get approved most smoothly when billed as day-care procedures with the diagnosis code attached (diabetic retinopathy, retinal tear, vein occlusion are all recognised indications) — our team files it correctly the first time. Details: cashless eye treatment in Mumbai · cashless guide.

Dr. Jignesh Gala and team at Topax Eye Hospital — cashless retina laser treatment Mumbai

9. Honest Side-Effects Talk (and the No-Scar Micropulse Option)

We tell every patient the truth about PRP’s trade-offs, because you deserve informed consent, not surprises: scatter laser works by sacrificing some peripheral retina to save the centre — so some patients notice reduced night vision or narrowed side vision, documented in 5-year visual-field studies (JAMA Ophthalmol, 2020; Retina review; complications review). Modern strategies minimise this: mild-scatter protocols (Int Ophthalmol), pattern-scanning shorter pulses, and combination therapy that reduces total laser needed.

For macular work, the game-changer is micropulse subthreshold laser — it stimulates healing without any burn or scar. The DIAMONDS trial found it non-inferior to conventional laser for suitable DME patients (Health Technol Assess, 2022), with 5-year durability data (2023) and combination RCTs with anti-VEGF (2024). If the idea of laser scars worries you, ask us whether you’re a micropulse candidate — very few Mumbai clinics even offer this conversation.

10. Why Dr. Jignesh Gala for Your Retina Laser

Dr. Jignesh Gala — retina laser specialist in Andheri West Mumbai, FRCS vitreoretinal surgeon

Dr. Jignesh Gala — FRCS (Ophth) Glasgow · MRCS Edinburgh · FICO London · DOMS (KEM Hospital) · MBBS (Grant Medical College)

Vitreoretinal & Cataract Surgeon | Founder & Director — Crystal Clear Eye Clinic & Topax Eye Hospital

Retina fellowship, L V Prasad Eye Institute · Former Asst. Professor, B.Y.L. Nair Hospital · Singapore-trained
BMJ Case Reports peer reviewer — your laser plan follows 2026 evidence (Protocol S, CLARITY, DIAMONDS), not 2006 habit (his research work)
Thousands of retinal lasers across India & Singapore — from 15-minute barrage to ROP laser in premature babies
Same-day emergency tear-laser pathway · evening hours · written cost plans

Explore: best retina specialist in Mumbai · retina treatment in Andheri · advanced retinal care · eye specialist in Andheri · retina surgery guide · vitrectomy surgery · vitreoretinal treatment · retina specialist profile · surgical videos · macular edema treatment.

Dr. Jignesh Gala in operation theatre scrubs — sterile retina laser protocol Andheri West

Operation theatre at Topax Eye Hospital — retina laser and surgery facility Mumbai

11. Location, Hours & Suburbs We Serve

Crystal Clear Eye Clinic — Laram Centre CHS, A1-202, Swami Vivekanand Rd, above Sunil Jewellers, near NADCO Shopping Centre, Railway Colony, Andheri West, Mumbai, Maharashtra 400058 · Open daily, closes 9 pm · Phone/WhatsApp: 077188 85245

Minutes from Lokhandwala, Four Bungalows, Seven Bungalows, Versova, Yari Road, DN Nagar, Juhu, JVPD, Vile Parle, Oshiwara, Jogeshwari, Goregaon; emergency tear-laser patients from Bandra, Santacruz, Khar, Malad, Kandivali, Powai, Thane, Navi Mumbai and across the Mumbai metropolitan region.

मराठी सारांश: रेटिना लेझर ही १०–२० मिनिटांची वेदनारहित OPD प्रक्रिया आहे — मधुमेह रेटिनोपॅथीसाठी PRP, रेटिना तडज गेल्यास बॅरेज लेझर (त्या दिवशीच!), आणि डाग न राहणारा मायक्रोपल्स लेझर. खर्च ₹3,000–₹25,000 (प्रकारानुसार). डॉ. जिग्नेश गाला (FRCS) स्वतः लेझर करतात. कॅशलेस: टोपॅक्स (डायरेक्ट) व क्रिस्टल क्लियर (TPA). फोन: 077188 85245.

हिंदी सारांश: रेटिना लेज़र 10–20 मिनट की बेदर्द OPD प्रक्रिया है — डायबिटिक रेटिनोपैथी के लिए PRP, रेटिना फटने पर बैराज लेज़र (उसी दिन!), और बिना निशान वाला माइक्रोपल्स लेज़र। लागत ₹3,000–₹25,000 (प्रकार अनुसार)। डॉ. जिग्नेश गाला (FRCS) स्वयं करते हैं। कैशलेस: Topax (डायरेक्ट) और Crystal Clear (TPA)। फोन: 077188 85245।

12. FAQs — Retina Laser Treatment in Andheri West, Mumbai

Is retina laser treatment painful?

Most patients rate it 2–4 out of 10 — pin-pricks and bright green flickers, not real pain. Numbing drops are used, modern pattern lasers are faster and gentler than old machines, and micropulse is nearly painless. Any mild ache settles within hours.

What is the cost of retina laser in Mumbai?

PRP: ₹3,000–8,000 per sitting (₹9,000–20,000 full course). Barrage laser for a retinal tear: ₹8,000–15,000 per eye. Focal/grid: ₹10,000–25,000. Micropulse: ₹12,000–25,000. YAG iridotomy: ₹5,000–10,000. Written itemised quote before treatment at our clinic.

Will retina laser remove my spectacles?

No — that’s LASIK, a completely different laser on the front of the eye. Retina laser treats disease at the back of the eye (bleeding, leakage, tears) and saves vision; it doesn’t change your glass power.

How urgent is a retinal tear? Can it wait a few days?

It should not wait. A tear can progress to retinal detachment within days, after which OPD laser is no longer enough — surgery becomes necessary. We keep same-day emergency barrage-laser slots; call 077188 85245 and mention flashes/floaters.

How long does a laser session take, and can I go to work after?

10–20 minutes of laser time (plus dilatation wait). Most people resume routine work the next day. Vision stays dazzled for 30–60 minutes after, so bring someone to drive you home if possible.

Laser or injections — which is better for diabetic retinopathy?

Both, used wisely. Injections act fast on swelling and bleeding; PRP laser gives durable long-term control and is far cheaper over 5 years. Trials (Protocol S, CLARITY, 2024–25 meta-analyses) guide our combined, staged approach — individualised to your OCT and angiography.

Does retina laser have side effects?

PRP can reduce night and peripheral vision (we use modern mild-scatter and combination protocols to minimise this). Focal laser near the macula carries a small risk of a blind spot if disease is very close to the centre — which is why we offer scar-free micropulse for suitable macular cases.

Is laser covered by insurance?

Yes, for recognised indications (diabetic retinopathy, retinal tear, vein occlusion) — usually as a day-care procedure. Direct cashless via Topax Eye Care (Vile Parle East), TPA cashless via Crystal Clear Eye Clinic (Andheri West). We file the paperwork.

How many laser sittings will I need?

Barrage for a tear: usually one. PRP: 2–3 sittings per eye. Focal/micropulse: 1–3 sessions. Your review scan decides if any touch-up is needed — most tear patients are one-and-done.

I have high minus power (-8). Should I get my retina lasered before LASIK?

High myopes have thinner peripheral retinas with more lattice degeneration. We do a dilated peripheral retina check first; if weak spots exist, barrage laser before any LASIK is the safe sequence. Many LASIK surgeons refer patients to us exactly for this.

Do you laser premature babies (ROP)?

Yes — Dr. Gala trained in ROP screening and laser at LV Prasad Eye Institute. ROP laser is time-critical; if your paediatrician or NICU has flagged your premature baby, call 077188 85245 the same day.

What is micropulse laser and is it available at your clinic?

Micropulse is a scar-free, subthreshold laser that treats macular swelling (DME, CSR) without burn marks — validated by the DIAMONDS trial. Yes, we offer it; very few Mumbai clinics discuss this option with patients.

Same-Day Retina Laser — Emergency Slots Daily

Crystal Clear Eye Clinic — Laram Centre CHS, A1-202, Swami Vivekanand Rd, above Sunil Jewellers, near NADCO Shopping Centre, Railway Colony, Andheri West, Mumbai 400058 · Open daily, closes 9 pm

📞 Call 077188 85245 💬 WhatsApp Appointment

Flashes or floaters? Say “emergency” — you’ll be seen today. Direct cashless: Topax Eye Care · TPA: Crystal Clear Eye Clinic

Medical disclaimer: This page is educational and not a substitute for examination. Prices are indicative Mumbai ranges (July 2026); your written quote after evaluation is final. Sudden flashes, floaters or a curtain over vision need same-day care.

13. Research & Evidence Library — 200+ Verified References

Every claim on this page is backed by verifiable sources — each link checked live. Browse by topic:

🔦 Retinal Laser Evidence — PubMed (68 verified)

🏛️ Global Authorities, Guidelines & Trial Registries (40 verified)

AAO (aao.org) — 7 links

AAO: Anti-VEGF Treatments — Plain-language explainer of what anti-VEGF eye injections are, conditions treated, and what to expect during the shot.
AAO: Diabetic Retinopathy: Causes, Symptoms, Treatment — Patient guide to diabetic eye disease stages, diagnosis (OCT), and treatments including anti-VEGF injections.
AAO: Understanding Macular Degeneration — Patient overview of dry vs wet AMD, AREDS2 vitamins, anti-VEGF therapy, and Amsler grid self-monitoring.
AAO: Retinal Vein Occlusion — Explains BRVO vs CRVO, macular edema, and anti-VEGF/laser treatment options for patients.
AAO: Diabetic Retinopathy PPP 2024 — AAO's official evidence-based clinical guideline for diabetic retinopathy care (free PDF).
AAO: Age-Related Macular Degeneration PPP 2024 (Updated 2026) — AAO's official AMD clinical guideline, including anti-VEGF treatment recommendations.
AAO: Retinal Vein Occlusions PPP 2024 (Updated 2026) — AAO's official RVO clinical guideline covering anti-VEGF agents and aflibercept 8 mg.

EyeWiki (eyewiki.org) — 5 links

EyeWiki: Intravitreal Injections — Physician-reviewed reference on injection technique, indications, and complications.
EyeWiki: Aflibercept — Drug monograph on Eylea: mechanism, dosing, trial evidence.
EyeWiki: Ranibizumab — Drug monograph on Lucentis: mechanism, indications, key trials.
EyeWiki: Faricimab — Drug monograph on Vabysmo, the dual VEGF/Ang-2 inhibitor.
EyeWiki: Endophthalmitis — Reference on the most serious injection complication: signs, management, prognosis.

ASRS (asrs.org) — 5 links

ASRS: Retina Health Series: Intravitreal Injections (fact sheet 30, PDF) — Patient fact sheet on what happens during an eye injection and its risks.
ASRS: Retina Health Series: Age-Related Macular Degeneration (fact sheet 16, PDF) — Patient fact sheet on AMD symptoms, testing, and anti-VEGF treatment regimens.
ASRS: Retina Health Series: Macular Edema (fact sheet 13, PDF) — Patient fact sheet on macular edema causes (incl. diabetes/DME) and treatments.
ASRS: Retina Health Series: Central Retinal Vein Occlusion (fact sheet 21, PDF) — Patient fact sheet on CRVO and its anti-VEGF/laser management.
ASRS: Diabetic Retinopathy (patient disease page) — ASRS patient portal page on diabetic retinopathy symptoms, causes, and treatments.

Retinal Physician (retinalphysician.com) — 3 links

Retinal Physician: Comparing Intravitreal Injection Protocols and Practices (Sept 2010) — Expert roundtable on injection technique nuances: anesthesia, asepsis, needle handling, post-op care.
Retinal Physician: Antisepsis for Intravitreal Injections (April 2023) — How povidone-iodine antisepsis lowers endophthalmitis risk from injections.
Retinal Physician: Endophthalmitis Then and Now (May 2025) — Historical-to-modern review of endophthalmitis prophylaxis and management.

Landmark journal article pages (DOI-resolving) — 6 links

Ophthalmology (AAO journal): Heier JS et al. — Intravitreal Aflibercept (VEGF Trap-Eye) in Wet AMD (VIEW 1/VIEW 2), 2012 — Pivotal trials that established aflibercept 2 mg for wet AMD.
Ophthalmology: Dugel PU et al. — HAWK and HARRIER: Phase 3 Trials of Brolucizumab for nAMD, 2020 — Trials leading to brolucizumab (Beovu) approval.
Lancet: Heier JS et al. — Faricimab in nAMD (TENAYA and LUCERNE), 2022 — Showed faricimab durability up to 16-week intervals in wet AMD.
Lancet: Wykoff CC et al. — Faricimab in DME (YOSEMITE and RHINE), 2022 — Pivotal faricimab trials in diabetic macular edema.
Ophthalmology: CATT Research Group — Ranibizumab and Bevacizumab for nAMD: Two-Year Results, 2012 — Head-to-head comparison of Lucentis vs Avastin for wet AMD.
Ophthalmology: Wells JA et al. (DRCR.net Protocol T) — Aflibercept, Bevacizumab, or Ranibizumab for DME, 2016 — Comparative-effectiveness trial guiding anti-VEGF choice in DME.

ClinicalTrials.gov (all confirmed via official v2 API) — 10 links

ClinicalTrials.gov: YOSEMITE — Faricimab in DME (COMPLETED) — Phase 3 faricimab trial in diabetic macular edema.
ClinicalTrials.gov: RHINE — Faricimab in DME (COMPLETED) — Sister phase 3 faricimab DME trial (official title: "A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema").
ClinicalTrials.gov: PHOTON — Aflibercept 8 mg in DME (COMPLETED) — Phase 3 high-dose aflibercept in diabetic eye disease.
ClinicalTrials.gov: PULSAR — Aflibercept 8 mg in wet AMD (COMPLETED) — Phase 3 high-dose aflibercept in neovascular AMD.
ClinicalTrials.gov: TENAYA — Faricimab in nAMD (COMPLETED) — Phase 3 faricimab in neovascular AMD.
ClinicalTrials.gov: LUCERNE — Faricimab in nAMD (COMPLETED) — Sister phase 3 faricimab nAMD trial.
ClinicalTrials.gov: HAWK — Brolucizumab (RTH258) vs aflibercept, Study 1 (COMPLETED) — Phase 3 brolucizumab trial in wet AMD.
ClinicalTrials.gov: HARRIER — Brolucizumab (RTH258) vs aflibercept, Study 2 (COMPLETED) — Sister phase 3 brolucizumab trial.
ClinicalTrials.gov: Archway — Port Delivery System (Susvimo) with ranibizumab, wet AMD (COMPLETED) — Phase 3 refillable ranibizumab implant vs monthly injections.
ClinicalTrials.gov: VIEW 1 — VEGF Trap-Eye (aflibercept) in wet AMD (COMPLETED) — Pivotal aflibercept wet AMD trial.

NEI (nei.nih.gov) — 2 links

NEI: Age-Related Macular Degeneration — NIH patient resource on AMD types, risk factors, and treatment.
NEI: Diabetic Retinopathy — NIH patient resource on diabetic eye disease and injections/laser/surgery.

MedlinePlus — 2 links

MedlinePlus: Macular Degeneration — Curated NIH patient information hub on AMD.
MedlinePlus: Diabetic Eye Problems — Patient hub on diabetic retinopathy and related eye complications.

💉 Combination Therapy — Injection Evidence (PubMed)

Aflibercept For Diabetic Macular Edema

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology, 2024.
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS. Retina (Philadelphia, Pa.), 2025.
Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis. European journal of ophthalmology, 2024.
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology, 2016.
Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. Current opinion in ophthalmology, 2025.
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. Ophthalmology, 2026.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet (London, England), 2024.
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. The New England journal of medicine, 2022.
Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema. Ophthalmology. Retina, 2025.
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology, 2020.

Faricimab (Vabysmo) Trials

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet (London, England), 2022.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology, 2024.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet (London, England), 2022.
Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial. Ophthalmology, 2026.
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology, 2019.
Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. Ophthalmology, 2024.
Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration. Ophthalmology, 2025.
Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials. Ophthalmology. Retina, 2025.
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024.

Ranibizumab Biosimilars

Approved biosimilar ranibizumab-a global update. Eye (London, England), 2023.
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation. Ophthalmology and therapy, 2022.
Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians? Eye (London, England), 2023.
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study. Journal of vitreoretinal diseases, 2025.
Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study). Eye (London, England), 2024.
Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review. Ophthalmology and therapy, 2021.
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs. Eye (London, England), 2024.
Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence. Ophthalmology and therapy, 2022.
FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings – FORCE study. Eye (London, England), 2025.
Biosimilar Ranibizumab and Innovator Ranibizumab-Immunogenicity Assessment and Its Impact on Safety and Efficacy. JAMA ophthalmology, 2023.

Anti-Vegf For Neovascular Amd

VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration. International journal of molecular sciences, 2025.
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era. Eye (London, England), 2024.
Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Science translational medicine, 2022.
Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Progress in retinal and eye research, 2021.
[Anti-VEGF therapy resistance in neovascular age-related macular degeneration]. Vestnik oftalmologii, 2017.
Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues. Eye (London, England), 2025.
Anti-angiogenic biomolecules in neovascular age-related macular degeneration; therapeutics and drug delivery systems. International journal of pharmaceutics, 2024.
Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization. Biomolecules, 2024.
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). The British journal of ophthalmology, 2014.
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug design, development and therapy, 2016.

Retinal Vein Occlusion Anti-Vegf

Integrated Assessment of OCT, Multimodal Imaging, and Cytokine Markers for Predicting Treatment Responses in Retinal Vein Occlusion Associated Macular Edema: A Comparative Review of Anti-VEGF and Steroid Therapies. Diagnostics (Basel, Switzerland), 2024.
[Retinal vein occlusion: anti-VEGF treatments]. Journal francais d'ophtalmologie, 2009.
Retinal Vein Occlusion. Developments in ophthalmology, 2016.
Use of Anti-VEGF Drugs in Retinal Vein Occlusions. Current drug targets, 2020.
Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials. Survey of ophthalmology, 2025.
Real-World Visual and Neovascularisation Outcomes from anti-VEGF in Central Retinal Vein Occlusion. Ophthalmic epidemiology, 2021.
Retinal vein occlusion. Handbook of clinical neurology, 2026.
Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2024.
[Long-term outcomes of anti-VEGF therapy for macular edema in retinal vein occlusion]. Vestnik oftalmologii, 2022.
Photocoagulation for retinal vein occlusion. Progress in retinal and eye research, 2021.

Dexamethasone Implant (Ozurdex)

Reverse engineering the Ozurdex dexamethasone intravitreal implant. International journal of pharmaceutics, 2023.
Dexamethasone intravitreal implant (OZURDEX(®)) for macular edema secondary to noninfectious uveitis: a review of the literature. Therapeutic delivery, 2019.
OZURDEX® (Dexamethasone Intravitreal Implant) 0.7 mg as Initial Therapy in Pseudophakic Patients With Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion, and Noninfectious Posterior Segment Uveitis: A Case-Based Discussion. Retina (Philadelphia, Pa.), 2019.
Intraoperative Dexamethasone Intravitreal Implant (Ozurdex) in Vitrectomy Surgery for Epiretinal Membrane. Current eye research, 2020.
CASE REPORT OF ABIOTROPHIA DEFECTIVA ENDOPHTHALMITIS AFTER REPEATED INJECTIONS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX). Retinal cases & brief reports, 2022.
PERSISTENT REMNANTS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX). Retina (Philadelphia, Pa.), 2020.
Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2014.
Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016.
Spontaneous extrusion of a dexamethasone intravitreal implant (Ozurdex). BMJ case reports, 2020.
Protracted Intralenticular Implant of Sustained-Release Dexamethasone Implant (Ozurdex). Klinische Monatsblatter fur Augenheilkunde, 2024.

Treat-And-Extend Anti-Vegf

Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis. Eye (London, England), 2023.
TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. Retina (Philadelphia, Pa.), 2015.
Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial. JAMA ophthalmology, 2024.
Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (London, England), 2023.
Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. Vision (Basel, Switzerland), 2019.
A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. Ophthalmology and therapy, 2017.
The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. International journal of molecular sciences, 2022.
Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis. Drug design, development and therapy, 2022.
Treat and Extend Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: To Stop or Not to Stop? Clinical & experimental ophthalmology, 2025.
Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta ophthalmologica, 2022.

Intravitreal Injection Real-World India

Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review. Clinical ophthalmology (Auckland, N.Z.), 2022.
Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases. Ophthalmology and therapy, 2021.
REal-world treatment outcomes after delayed intRavitreal therapy in center-involving diabetic macular edema – RETORT study. International journal of retina and vitreous, 2023.
"Real world outcomes of intravitreal brolucizumab for persistent diabetic macular edema". International journal of retina and vitreous, 2025.
Real-world experience of brolucizumab in nAMD. Indian journal of ophthalmology, 2024.
Real-world outcomes of intravitreal anti-vascular endothelial growth factor monotherapy in proliferative type 2 macular telangiectasia. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021.
Ranizurel safety evaluation in real-world -(RaSER) study. American journal of ophthalmology case reports, 2022.
Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world study. Indian journal of ophthalmology, 2024.
Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian journal of ophthalmology, 2017.
Factors determining compliance with recommended intravitreal injections for retinal diseases among out-of-pocket, fully subsidized (non-paying), and insured patients: Real-world evidence from India. Indian journal of ophthalmology, 2025.

drjigneshgala@gmail.com

See Full Bio